الصفحة الرئيسية>>Signaling Pathways>> Chromatin/Epigenetics>> Epigenetic Reader Domain>>IACS-9571 Hydrochloride (ASIS-P040 Hydrochloride)

IACS-9571 Hydrochloride (ASIS-P040 Hydrochloride)

رقم الكتالوجGC34437

Products are for research use only. Not for human use. We do not sell to patients.

IACS-9571 Hydrochloride (ASIS-P040 Hydrochloride) التركيب الكيميائي

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
481٫00
متوفر
1mg
110٫00
متوفر
5mg
321٫00
متوفر
10mg
597٫00
متوفر
50mg
2068٫00
متوفر
100mg
3033٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

IACS-9571 Hydrochloride is a potent and selective inhibitor of TRIM24 and BRPF1, with an IC50 of 8 nM for TRIM24, and Kds of 31 nM and 14 nM for TRIM24 and BRPF1, respectively.

IACS-9571 Hydrochloride shows excellent cellular potency with EC50 of 50 nM. IACS-9571 Hydrochloride (1 μM) has potent activities against a panel of 32 bromodomains. IACS-9571 Hydrochloride is a selective dual TRIM24/BRPF1 inhibitor (Kd=1.3/2.1 nM) with 9- and 21-fold selectivity against BRPF2 and BRPF3, respectively. IACS-9571 Hydrochloride does not interact with the BET sub-family of bromodomains, displaying greater than 7700-fold selectivity versus BRD4 (1, 2) relative to TRIM24[1].

[1]. Palmer WS, et al. Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor. J Med Chem. 2016 Feb 25;59(4):1440-54.

مراجعات

Review for IACS-9571 Hydrochloride (ASIS-P040 Hydrochloride)

Average Rating: 5 ★★★★★ (Based on Reviews and 17 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for IACS-9571 Hydrochloride (ASIS-P040 Hydrochloride)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.